Biotechnology Company Announces Successful Clinical Trial Completion For Leukemia Treatment

In a significant stride toward combating refractory/relapsed acute myeloid leukemia (AML), Bio-Path Holdings, Inc. has recently announced the successful completion of the second dose cohort in the dose escalation portion of its Phase 1/1b clinical trial of BP1002. This marks a pivotal moment in the ongoing battle against one of the most challenging forms of leukemia, particularly for patients who have developed resistance to existing treatments like venetoclax. $Bio-Path Holdings(BPTH.US)$